Company Name, Ticker, Suppliers, else..

Kuvatris Therapeutics Inc (PXMD)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Kuvatris Therapeutics Inc 's

Name: Kuvatris Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PXMD Sales vs. its Competitors Q3 2024

Comparing the current results to its competitors, Kuvatris Therapeutics Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.2 %, recorded in the same quarter.

• List of PXMD Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Kuvatris Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 1410.55 %

<< PXMD Stock Performance Comparisons

Kuvatris Therapeutics Inc 's Comment on Competition and Industry Peers

The company operates in the pharmaceutical industry, facing competition from commercial pharmaceutical and biotechnology companies, academic institutions, government agencies, and research organizations. Competitors often have greater resources and more advanced product candidates. In the development of PAX-101 for treating autism spectrum disorder (ASD), there is currently no FDA-approved medication for core symptoms, but several companies are developing competing drugs. Notable competitors in ASD include CureMark LLC, which is conducting Phase 3 studies for CM-AT; Yamo Pharmaceuticals, with Phase 2 studies for LI-79; and GW Pharmaceuticals, conducting Phase 2 studies for Cannabidivarin.

<< See the full list of PXMD competitors

*Market share is calculated based on total revenue.

PXMD's Stock Performance relative to its Competitors

Publicly Traded Peers of Kuvatris Therapeutics Inc

Y mabs Therapeutics inc
Share Performance

-33.82%

One Year

Y mabs Therapeutics inc

Profile

Ymabs Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.

More about Y mabs Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 390.188 mill.	$ 84.721 mill.	$ -22.223 mill.

Cypherpunk Technologies Inc
Share Performance

+281.17%

30 Days

Cypherpunk Technologies Inc

Profile

Cypherpunk Technologies develops privacy technologies and digital asset strategies with a focus on Zcash.

More about Cypherpunk Technologies Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 536.837 mill.	$ - mill.	$ -0.877 mill.

G1 Therapeutics Inc
Share Performance

+379.87%

One Year

G1 Therapeutics Inc

Profile

G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.

More about G1 Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 375.198 mill.	$ 58.195 mill.	$ -44.770 mill.

Enlivex Therapeutics Ltd
Share Performance

+47.19%

This Quarter

Enlivex Therapeutics Ltd

Profile

Enlivex Therapeutics Ltd's business model focuses on developing and commercializing novel immune system therapies.

More about Enlivex Therapeutics Ltd's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3.298 mill.	$ - mill.	$ 1,235.528 mill.

Opus Genetics Inc
Share Performance

+179.48%

This Year

Opus Genetics Inc

Profile

Opus Genetics develops gene therapies for inherited retinal diseases and other ophthalmic disorders.

More about Opus Genetics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 659.950 mill.	$ 9.856 mill.	$ -114.997 mill.

163 more competitors available

Sources: Kuvatris Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 14, 2026 8:16 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kuvatris Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.